Dear Editor,
============

Renal cell carcinoma (RCC) accounts for ∼3% of adult malignancies and 90%-95% of kidney neoplasms^[@bib1]^. Metastatic disease is usually resistant to radiation and chemotherapy. Immunotherapy shows limited response rates of 15% to 20%^[@bib2]^. Cancer stem-like cells (CSCs) are key players in RCC initiation, development and resistance to therapy^[@bib3]^. Previous studies have shown that RCC is a genetically distinct adult carcinoma with a relatively low mutation rate^[@bib4]^. Sequencing analyses have revealed that some common somatic mutations are shared among RCC patients^[@bib5]^. Recently, single-cell exome sequencing has been used to evaluate somatic mutations in many tumor types^[@bib6]^. However, a systematic effort applying this new technique to identify key driver genes in the CSCs of RCC has not been made.

CD133 has been identified as a common CSC marker for many solid tumors, including kidney cancer^[@bib7]^. We investigated whether CD133^+^ RCC cells isolated from patients showed stem-like characteristics. We sorted CD133^+^ and CD133^−^ RCC cells from the specimens of a 57-year-old male patient diagnosed with stage T3aN1M0 RCC ([Supplementary information, Figure S1A](#sup1){ref-type="supplementary-material"} and [Supplementary information, Table S1A](#sup1){ref-type="supplementary-material"}), and only CD133^+^ cells had sphere-forming capability ([Supplementary information, Figure S1A](#sup1){ref-type="supplementary-material"}). We next grafted isolated CD31^−^CD45^−^, CD31^−^CD45^−^CD133^−^, or CD31^−^CD45^−^CD133^+^ RCC cells subcutaneously into NOD/SCID mice. Nearly all mice that received 10 000 CD31^−^CD45^−^CD133^+^ cells developed visible tumors, and among mice that received only 10 cells, ∼25% developed visible tumors ([Supplementary information, Figure S1B](#sup1){ref-type="supplementary-material"}). However, more than 50% of the mice transplanted with the other two cell types (10 000 cells/mouse) remained tumor-free ([Supplementary information, Figure S1B](#sup1){ref-type="supplementary-material"}). In addition, to directly evaluate the frequency of stem-like RCC cells, we applied an extreme limiting dilution assay. We estimated the percentage of CSCs in the CD31^−^CD45^−^CD133^+^ cell sample was more than seven fold higher than in the other two cell types ([Supplementary information, Figure S1C](#sup1){ref-type="supplementary-material"}), indicating that CD133^+^cells isolated from RCC have stem-like properties.

We next sorted 10 CD133^+^ RCC cells, 10 CD133^−^ RCC cells, and 10 normal renal cells from the same patient for single-cell whole-exome sequencing (WES). The RCC and adjacent normal tissues of the same patient were also subjected to WES ([Supplementary information, Figure S1D](#sup1){ref-type="supplementary-material"}). For each cell and tissue sample, we acquired WES data with over 140× coverage after whole-genome amplification (WGA) using the MALBAC technique.

To eliminate the false-positive variations arising from WGA, we only selected single-nucleotide variants (SNVs) present in CD133^+^ or CD133^−^ RCC cells but absent in normal cells. Similarly, for whole-tissue WES analysis, SNVs specifically present in the RCC tissue were chosen. WES of the cancer tissue revealed 160 somatic SNVs and single-cell sequencing of the 20 tumor cells identified 297 somatic SNVs ([Supplementary information, Figure S1E](#sup1){ref-type="supplementary-material"}). Commonly mutated genes in RCC, such as *VHL*, *BAP1*, *TRA* and *CHD4*, were found to carry variations in both RCC single cells and tissue samples, demonstrating the reliability of our WES analysis ([Supplementary information, Table S1B](#sup1){ref-type="supplementary-material"}). Among the SNVs in single cells, 141 were located in coding regions. These SNVs were more enriched in CD133^+^ cells than in CD133^−^ cells ([Figure 1A](#fig1){ref-type="fig"} and [1C](#fig1){ref-type="fig"}). More importantly, we discovered several coding region mutations that are unique to CD133^+^ RCC cells. Among them, three missense mutations, c.A241T\>p.R81W in *Kielin/chordin-like protein* (*KCP*), c.G316A\>p.G106S in *LOC440563* and c.A406T\>p.N136Y in *LOC440040*, have not been reported in RCC. While other mutations in *KCP* can be found in the RCC TCGA database (c.G2590A\>p.A864T, c.C1250G\>p.A417G, and c.A2680G\>p.R894G), no mutations in *LOC440563* and *LOC440040* have been linked to RCC and other cancer before ([Figure 1A](#fig1){ref-type="fig"}, [Supplementary information, Table S1C](#sup1){ref-type="supplementary-material"}). In addition, we found that *KCP* and *LOC440040* mutations could be detected in both single cells and in the original cancer tissue ([Figure 1A](#fig1){ref-type="fig"} and [Supplementary information, Table S1B](#sup1){ref-type="supplementary-material"}). Furthermore, we identified that C/G\>T/A, A/T\>C/G and A/T\>G/C transitions were the most common mutations in RCC ([Figure 1B](#fig1){ref-type="fig"}). Notably, the A/T\>T/A transitions were significantly more frequent in CD133^+^ cells than in CD133^−^ cells ([Figure 1B](#fig1){ref-type="fig"}, *P* = 0.31 × 10^−9^).

To further confirm that the isolated single cells are indeed tumor cells, we performed principle component analysis of all somatic mutation data obtained from the 30 cells ([Figure 1D](#fig1){ref-type="fig"}). The normal renal and CD133^−^ RCC cells formed two independent groups, whereas the CD133^+^ RCC cells were scattered and were different from these two groups ([Figure 1D](#fig1){ref-type="fig"}). We constructed a neighbor-joining tree for the 30 cells; in the tree, the 10 normal cells were grouped together, whereas both sets of 10 CD133^+^ RCC cells and 10 CD133^−^ RCC cells were nearly completely separated between the groups ([Figure 1E](#fig1){ref-type="fig"}). The evolution distance between normal cells and CD133^+^ RCC is larger than that between normal cells and CD133^−^ RCC, suggesting that CD133^+^ RCC cells more likely originated from cancer cells than normal cells.

We then selected mutated genes that are shared bymore than three cells in each group for further analysis. Twenty-nine mutated genes were detected in more than 3 CD133^+^ RCC cells ([Figure 1F](#fig1){ref-type="fig"} and [Supplementary information, Table S1C](#sup1){ref-type="supplementary-material"}), while only 11 mutated genes were shared by over 3 CD133^−^ RCC cells (data not shown). Among the 29 mutated genes detected in CD133^+^ RCC cells, 18 genes, including *KCP* (not *LOC440563* or *LOC44004*0), were listed in the TCGA RCC database as mutated genes, and the frequency of the 18 mutated genes in the 416 RCC cases in TCGA was less than 2% ([Supplementary information, Table S1D](#sup1){ref-type="supplementary-material"}).

To determine the tumor-propagating potential of each mutation, we introduced heterozygous mutations in the 20 candidate genes, which are related to the function of chromatin remodeling, transcription regulation and self-renewal, in RCC 786-O cells using the CRISPR-Cas9 technique (one mutation/gene), and assay for single cell spherogenicity. In all, 3 out of 20 gene mutations are nonsense mutations and the remaining are missense mutations ([Supplementary information, Table S1C](#sup1){ref-type="supplementary-material"}). All 20 mutations introduced by the CRISPR-Cas9 system were verified by DNA sequencing ([Figure 1H](#fig1){ref-type="fig"} and [Supplementary information, Figure S2](#sup1){ref-type="supplementary-material"}). Two of the 20 mutations in 786-O cells significantly enhanced the spherogenesis capabilities by more than 10% ([Figure 1G](#fig1){ref-type="fig"}, left). The mutation with the highest cancer spherogenesis was in the *KPC* gene. Because multiple mutations may be required for the maintenance and development of CD133^+^ RCC cells, we mutated each of the remaining 19 genes in combination with *KPC*. The *LOC440040* mutation was most effective, which enhanced spherogenesis capabilities of the *KPC* mutation ([Figure 1G](#fig1){ref-type="fig"}, middle). We also additionally mutated *LOC440563* and found *KPC-LOC440040-LOC440563* triple mutation could increase the sphere-formation abilities by more than 30% ([Figure 1G](#fig1){ref-type="fig"}, right). To validate that *KCP* is indeed a prominent driver gene among the 20 candidates, we mutated the *LOC440040* and one of the other 19 genes and found that *LOC440040* plus *KCP* double mutations had significantly higher spherogenesis than other combination. Consistently, combining the *KPC* mutation could increase the sphere-forming ability of cells with the *LOC440040-LOC440563* double mutations ([Supplementary information, Figure S1F](#sup1){ref-type="supplementary-material"}). Moreover, 786-O and 769-P RCC cells with *KCP/LOC440040/LOC440563* triple mutations had significant enhancement in cancer spherogenesis capabilities compared with wild-type cells ([Figure 1I](#fig1){ref-type="fig"}). Results of xenograft experiments confirmed that more mice developed tumors and had higher enrichment of CSCs in the group that received triple-mutated 786-O or 769-P cells compared with mice that received wild-type cells ([Figure 1J](#fig1){ref-type="fig"}), indicating that mutations in the three genes played a key role in the CD133^+^ RCC tumor-propagating features. Taken together, these results suggest that mutations in *KCP, LOC440040* and *LOC4405*63 may facilitate RCC cells to acquire CSC properties.

Next, we assessed the mutation rates of *KCP*, *LOC440040*, and *LOC440563* in a cohort of 57 RCC patients. CD133^+^ RCC cells in each patient were sorted and subjected to targeted Sanger sequencing. More than 20% of the patients harbored at least one mutation ([Figure 1K](#fig1){ref-type="fig"}) and 5.26% (3/57) harbored all three mutations ([Supplementary information, Table S1A](#sup1){ref-type="supplementary-material"}). The patients with triple mutations showed a significantly shorter tumor-free time after primary tumor resection ([Figure 1L](#fig1){ref-type="fig"}). The outside region mutations in RCC remain to be investigated in the future because of the current limitations of targeted Sanger sequencing.

In summary, using single-cell exome sequencing, we discovered that CD133^+^ RCC cells have CSC properties and likely originate from cancer cells instead of from normal renal cells. *KCP*, *LOC440040*, and *LOC440563* mutations are novel renal cancer stem cell drivers. *LOC440563* encodes an RNA-binding protein, which belongs to the subfamily of heterogeneous nuclear ribonucleoproteins (hnRNPs). It influences pre-mRNA processing, metabolism and transport^[@bib8],[@bib9]^. *LOC440563* is significantly mutated in colon cancer; however, the mutations are different from what we identified in RCC CSCs^[@bib10]^. Considering the contribution of the hnRNP family to DNA damage repair^[@bib11]^, it is possible that the *LOC440563* mutation may drive CSC stemness via impairing the DNA repair process. *LOC440040* is a GRM5 (glutamate receptor, metabotropic 5) pseudogene. GRM5 belongs to the mGluR family, and dysregulated glutamatergic signaling is involved in many cancer types, such as glioma and melanoma^[@bib12]^. However, the relationship between LOC440040 and cancer is currently unknown. It would be interesting to determine whether mutant LOC440040 affects glutamatergic signaling in RCC CSC populations. *KCP* encodes a secreted protein, which plays complex roles in the regulation of the TGF-β pathway. Abnormal level of KCP may cause myriad renal pathology and cancer^[@bib13],[@bib14],[@bib15]^. It would be interesting to study whether the *KCP* mutation identified in this work promotes CSC self-renewal via impacting TGF-β signaling. Finally our study indicates *KCP*, *LOC440040*, *LOC440563* mutations, which are present in at least 20% of patients in our survey, constitute robust and dangerous drivers promoting reprogramming of RCC cancer cells into CSCs. They thus should serve as important prognostic factors and therapeutic targets for RCC.
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![Identification of driver genes in renal cell carcinoma stem cells via single-cell exome sequencing. **(A)** Detection of somatic mutations in CD133^+^CD133^−^ RCC cells and in cancer tissue. The main plot shows information for genes with mutations for 20 cells and original cancer tissue. The red color represents non-silent mutations and green color represents silent mutations. **(B)** Somatic mutation graph. Two substitutions (A/T\>G/C and C/G\>T/A) are clearly frequent. **(C)** Venn plots show the somatic mutations in CD133^+^ and CD133^−^ RCC cells. **(D)** Principle component analysis (PCA) of the mutations in the CD133^+^ RCC cells (red), CD133^−^ RCC cells (green) and normal cells (blue). Eigenvector is defined as the Covariance Matrix. **(E)** A neighbor-joining tree was constructed using the somatic mutation data set. The normal cells are labeled in green, CD133^−^ RCC cells are labeled in blue, and CD133^+^ RCC cells are labeled in red. **(F)** The average mutation frequency of 29 genes with variations in at least 3 CD133^+^ RCC cells. The mutation frequency indicates the percentage of CD133^+^ RCC cells with the mutated gene. **(G)** Data points indicate the average number of spheres of RCC cells with distinct mutations in serum-free conditions. Each of the 20 mutations was tested alone (first column, \'single mutation\'), in combination with a *KCP* mutation (second column) or in combination with *KCP* and *LOC440040* mutations (third column). Other mutations were also tested in combination with *KCP*, *LOC440040*, and *LOC440563* mutations (fourth column). Mutation combinations that enhanced the *in vitro* spherogenicity (blue) were selected for *in vivo* validation. CD133^+^ cells spheres served as the positive control (red). **(H)** Representative Sanger-sequencing data of *KCP*, *LOC440040*, and *LOC440563* in wild-type (WT) and mutated (Mut) renal cancer cells are listed below. **(I)** Representative oncospheres in mutated (Mut) and vehicle renal cancer cells. **(J)** The 18-week tumor-free rate of NOD/SCID mice after subcutaneous injection at the indicated dilutions of 786-O WT, 786-O Mut, 769-P WT, and 769-P cells (left panel, *n* = 6 mice per group). The estimated percentage of CSCs in 786-O WT, 786-O Mut, 769-P WT, and 769-P Mut cells in xenografted mice using extreme limiting dilution analysis (*n* = 6 grafted tumors per dilution; right panel). **(K)** The CD31^−^CD45^−^CD133^+^ cells from 57 RCC patients were individually sorted and pooled together for the indicated targeted sequencing. The mutation rates of *KCP*, *LOC440040*, and *LOC440563* are indicated. **(L)** The average tumor-free time of 57 renal cancer patients with or without *KCP*, *LOC440040*, and/or *LOC440563* mutation(s) after primary tumor resection.](cr2016150f1){#fig1}
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